Microvast Holdings announces departure of chief financial officer
Pluri Inc. (NASDAQ:PLUR), a biotechnology firm specializing in biological products, has announced its 2025 Annual Meeting of Shareholders will take place on Wednesday, May 14, 2025, at the company’s headquarters in Haifa, Israel. The meeting is scheduled for 5:00 p.m. local time. The announcement comes as the company, currently valued at $31.4 million, shows promising signs with analysts expecting profitability this year, according to InvestingPro data.
This year’s meeting date signifies a shift of more than 30 days from the previous year’s annual meeting. The record date, which is the deadline for shareholders to be eligible to receive notice and vote at the meeting, has been set for the close of business on March 24, 2025. The company’s stock has experienced significant volatility, with a 41.67% decline over the past year, though InvestingPro analysis suggests the stock is currently undervalued.
Shareholder proposals intended for inclusion in the proxy materials were required to be submitted by January 2, 2025. This deadline was established to allow sufficient time for the company to prepare and distribute proxy materials as per SEC regulations. Proposals had to comply with both the SEC’s rules and the company’s bylaws.
The January 2 deadline was also critical for determining the timeliness of shareholder proposals for the purposes of discretionary proxy voting and meeting the notice requirements under SEC rules.
The announcement, made in a recent SEC filing, confirms Pluri Inc.’s adherence to corporate governance practices and regulatory requirements regarding shareholder engagement and participation in company affairs.
The information is based on a press release statement.
In other recent news, Pluri Inc. has entered into an exclusive partnership with Hemafund Ltd. to address the urgent need for radiation countermeasures in Ukraine. This collaboration focuses on stockpiling and potentially advancing Pluri’s PLX-R18 cell therapy for treating Hematopoietic Acute Radiation Syndrome. The agreement, initially set for three years, involves Pluri producing the therapy while Hemafund manages storage and distribution. The companies aim to secure funding for a stockpile of 12,000 doses, potentially generating over $100 million in value. Additionally, Pluri Inc. has been granted an extension by Nasdaq to meet the exchange’s continued listing requirements after receiving a deficiency notice for not maintaining the minimum required stockholders’ equity. The company has until May 24, 2025, to regain compliance or face potential delisting, although it may appeal the decision. Pluri’s management is committed to taking necessary measures to maintain its Nasdaq listing. These developments reflect the company’s ongoing efforts to navigate regulatory and market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.